• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Regulatory press release

SpectraCure: Looking for excellent, highly-skilled education and training in the vibrant field of Biophotonics? Apply now!

SpectraCure
Read the release

Apply to The European Training Network PHAST (Photonics for Healthcare: multiscAle cancer diagnosiS and Therapy). Maybe you will be one of 15 Early Stage Researchers (ESRs) which will be enrolled in a strong multidisciplinary PhD programme.

Position #12 is at SpectraCure
Development of advanced online dosimetry algorithms for photodynamic therapy of tumours.

Brief description of the project
The objective of the ESR project is to further develop the dosimetry algorithms that are now used in clinical trials, by retrospective analysis of the treatment outcome and improvement of the models and numerical methods in the algorithms.

The activity will include analysis of medical data, optimization, model development and software implementation, tissue optical measurements, and field work in clinics.
Planned secondments at Lund University (Sweden), Politecnico di Milano (Italy), and Tyndall Institute (Ireland). For further information, https://phast-etn.eu/vacancies/12/esr-12

 

SpectraCure is a world-leader in research and development of dosimetry algorithms for photodynamic therapy (PDT) of internal cancer tumours. The work is conducted in collaboration with academic groups and hospitals in Europe and North America. www.spectracure.com (https://spectracure.com/technology/)

 

[image]